IL216885D0 - Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases - Google Patents

Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases

Info

Publication number
IL216885D0
IL216885D0 IL216885A IL21688511A IL216885D0 IL 216885 D0 IL216885 D0 IL 216885D0 IL 216885 A IL216885 A IL 216885A IL 21688511 A IL21688511 A IL 21688511A IL 216885 D0 IL216885 D0 IL 216885D0
Authority
IL
Israel
Prior art keywords
pyridine
treatment
use
rheumatoid arthritis
inter alia
Prior art date
Application number
IL216885A
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US22048809P priority Critical
Priority to PCT/US2010/039942 priority patent/WO2010151740A2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL216885D0 publication Critical patent/IL216885D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulfur or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
IL216885A 2009-06-25 2011-12-08 Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases IL216885D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US22048809P true 2009-06-25 2009-06-25
PCT/US2010/039942 WO2010151740A2 (en) 2009-06-25 2010-06-25 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
IL216885D0 true IL216885D0 (en) 2012-03-01

Family

ID=43066540

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216885A IL216885D0 (en) 2009-06-25 2011-12-08 Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases

Country Status (16)

Country Link
US (2) US20100331306A1 (en)
EP (1) EP2445900B1 (en)
JP (1) JP2013527123A (en)
KR (1) KR20140068742A (en)
AR (1) AR077267A1 (en)
AU (1) AU2010265974B2 (en)
BR (1) BRPI1016150A2 (en)
CA (1) CA2781865A1 (en)
EA (1) EA201270013A1 (en)
IL (1) IL216885D0 (en)
MX (1) MX2011013510A (en)
SG (1) SG176986A1 (en)
TW (1) TW201111362A (en)
UY (1) UY32743A (en)
WO (1) WO2010151740A2 (en)
ZA (1) ZA201200611B (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5732701B2 (en) 2007-03-23 2015-06-10 アムジエン・インコーポレーテツド 3-Substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
BRPI0809141A2 (en) * 2007-03-23 2014-08-26 Amgen Inc Compound, manufacture of a medicinal product, and pharmaceutical composition
ES2474147T3 (en) * 2008-05-30 2014-07-08 Amgen, Inc PI3 kinase inhibitors
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
EP2445898A2 (en) 2009-06-25 2012-05-02 Amgen, Inc 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
CN102482278B (en) 2009-06-29 2015-04-22 因塞特公司 Pyrimidinones as PI3K inhibitors
JP2013514989A (en) 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド Heterocyclic compounds and uses thereof
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
UY33304A (en) 2010-04-02 2011-10-31 Amgen Inc Heterocyclic compounds and their uses
AR081823A1 (en) 2010-04-14 2012-10-24 Incyte Corp Fused derivatives as inhibitors of PI3Kd
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JO2998B1 (en) 2010-06-04 2016-09-05 Amgen Inc Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US20130079342A1 (en) * 2010-06-30 2013-03-28 Paul John Dransfield Heterocyclic compounds and their uses
EP2588467A1 (en) * 2010-07-01 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US8765768B2 (en) * 2010-11-17 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
MX2013007261A (en) * 2010-12-23 2013-11-04 Amgen Inc Heterocyclic compounds and their uses.
CN102070520A (en) * 2011-01-14 2011-05-25 华东师范大学 Method for preparing 3-aryl-subsituted quinoline by 3-oxo-2,3-diarylpropionaldehyde
WO2012100732A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
EA201690655A1 (en) * 2011-05-04 2017-01-30 Ризен Фармасьютикалз Са New connections as proteinkinase modulators
JP6029668B2 (en) 2011-08-29 2016-11-24 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and uses thereof
KR101982475B1 (en) 2011-09-02 2019-05-27 인사이트 홀딩스 코포레이션 Heterocyclylamines as pi3k inhibitors
US9056817B2 (en) * 2011-09-12 2015-06-16 Council Of Scientific And Industrial Research Arylated β-dicarbonyl compounds and process for the preparation thereof
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
JP6117235B2 (en) 2011-12-15 2017-04-19 ノバルティス アーゲー Use of inhibitors of PI3K activity or function
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas bicyclic inhibitors of PI3K
EP2834231B1 (en) * 2012-04-04 2016-03-30 Amgen Inc. Heterocyclic compounds and their uses
UY34893A (en) 2012-07-10 2014-02-28 Takeda Pharmaceutical Azaindole derivatives
BR112015008308A2 (en) 2012-10-16 2017-12-05 Janssen Pharmaceutica Nv methylene-linked quinolinyl modulators of ror-gamma-t
CA2888480A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of ror.gamma.t
WO2014062667A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
EP2916868A1 (en) 2012-11-08 2015-09-16 Rhizen Pharmaceuticals S.A. Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
EP2941426B1 (en) 2012-12-21 2018-06-13 Gilead Calistoga LLC Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014100767A1 (en) 2012-12-21 2014-06-26 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2906538A1 (en) 2013-03-14 2014-09-25 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2915129A1 (en) 2013-06-14 2014-12-18 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CN105636952A (en) 2013-10-15 2016-06-01 詹森药业有限公司 Secondary alcohol quinolinyl modulators of roryt
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9944639B2 (en) 2014-07-04 2018-04-17 Lupin Limited Quinolizinone derivatives as PI3K inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
SG11201706917WA (en) 2015-02-27 2017-09-28 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
TW201636339A (en) 2015-03-06 2016-10-16 Nanjing Sanhome Pharmaceutical Co Ltd Substituted pyrimidine compounds as phosphatidylinositol 3-kinase δ inhibitor and use thereof
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2017155741A1 (en) * 2016-03-05 2017-09-14 Zhejiang Vimgreen Pharma Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
US20190135833A1 (en) 2016-06-08 2019-05-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3478659A1 (en) * 2016-07-04 2019-05-08 Bayer CropScience Aktiengesellschaft Benzosultams and analogues and their use as fungicides
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE3020458C2 (en) 1980-05-29 1986-07-31 Herzog, Thomas, Prof. Dr., 3500 Kassel, De
TW232013B (en) 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
NO306992B1 (en) 1993-01-28 2000-01-24 Takeda Chemical Industries Ltd Quinoline derivatives, farmasoeytiske compositions containing the compounds and to the use of compounds
AU1860995A (en) 1994-03-08 1995-09-25 Takeda Chemical Industries Ltd. Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
US6384251B1 (en) * 1998-03-18 2002-05-07 Humanetics Corporation Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
US6355636B1 (en) * 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
JP5732701B2 (en) * 2007-03-23 2015-06-10 アムジエン・インコーポレーテツド 3-Substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
BRPI0809141A2 (en) * 2007-03-23 2014-08-26 Amgen Inc Compound, manufacture of a medicinal product, and pharmaceutical composition
JP5564947B2 (en) 2007-09-26 2014-08-06 アステラス製薬株式会社 Quinolone derivatives
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
GB0821693D0 (en) * 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents
ES2598358T3 (en) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Quinoline derivatives as PI3K kinase inhibitors
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
ES2534096T3 (en) 2009-11-12 2015-04-17 Ucb Pharma, S.A. Condensed bicyclic pyridine and pyrazine derivatives as kinase inhibitors
JP2013514989A (en) * 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド Heterocyclic compounds and uses thereof
EP2588467A1 (en) * 2010-07-01 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity

Also Published As

Publication number Publication date
JP2013527123A (en) 2013-06-27
MX2011013510A (en) 2012-03-07
UY32743A (en) 2010-12-31
US20160333017A1 (en) 2016-11-17
WO2010151740A2 (en) 2010-12-29
AU2010265974B2 (en) 2014-09-11
CA2781865A1 (en) 2010-12-29
US20100331306A1 (en) 2010-12-30
WO2010151740A4 (en) 2011-05-19
EA201270013A1 (en) 2012-06-29
EP2445900B1 (en) 2016-03-02
AR077267A1 (en) 2011-08-17
AU2010265974A1 (en) 2012-01-19
US9873704B2 (en) 2018-01-23
ZA201200611B (en) 2012-10-31
SG176986A1 (en) 2012-02-28
BRPI1016150A2 (en) 2016-04-19
KR20140068742A (en) 2014-06-09
TW201111362A (en) 2011-04-01
EP2445900A2 (en) 2012-05-02
WO2010151740A3 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
DK2440467T3 (en) Container and method of making the same
HK1153842A1 (en) Glass substrates and methods of annealing the same
EP2445568A4 (en) Steerable medical delivery devices and methods of use
PL3001903T3 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
BR112012031194A2 (en) cysteamine derivatives and their use in the treatment of ehna
EP2430112A4 (en) Materials and methods for the preparation of nanocomposites
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
EP2398494A4 (en) Proproteins and methods of use thereof
EP2613735A4 (en) Devices and methods for the treatment of vascular defects
ZA201206775B (en) Pyridine and pyrazine derivative for the treatment of cf
EP2191458A4 (en) Finger-worn devices and related methods of use
IL222006A (en) Conjugates of pyrrolobenzodiazepines and their use in therapy
EP2187742A4 (en) Benzylbenzene derivatives and methods of use
IL223215A (en) Nanowire catalsyts and methods of producing the same
GB0817584D0 (en) Apparatus for the rotation of objects to allow inspection and/or treatment thereof
PL2544698T3 (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
EP2440050A4 (en) Triazine derivatives and their therapeutical applications
EP2512369B8 (en) Graft devices and methods of use
GB0814364D0 (en) Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
SI2544682T1 (en) Phytocannabinoids in the treatment of cancer
IL213971D0 (en) Modular dna-binding domains and methods of use
EP2501763A4 (en) Protective coatings and methods of making and using the same
EP2277049A4 (en) Autoantibodies in the detection and treatment of cancer
IL216972A (en) Implantable drug delivery devices and methods of making the same
EP2408384A4 (en) Pedicle screws and methods of using the same